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Summary
Background—Use of antiretroviral treatment for HIV-1 infection has decreased AIDS-related
morbidity and mortality and prevents sexual transmission of HIV-1. However, the best time to
initiate antiretroviral treatment to reduce progression of HIV-1 infection or non-AIDS clinical
events is unknown. We reported previously that early antiretroviral treatment reduced HIV-1
transmission by 96%. We aimed to compare the effects of early and delayed initiation of
antiretroviral treatment on clinical outcomes.
Methods—The HPTN 052 trial is a randomised controlled trial done at 13 sites in nine countries.
We enrolled HIV-1-serodiscordant couples to the study and randomly allocated them to either
early or delayed antiretroviral treatment by use of permuted block randomisation, stratified by site.
Random assignment was unblinded. The HIV-1-infected member of every couple initiated
antiretroviral treatment either on entry into the study (early treatment group) or after a decline in
CD4 count or with onset of an AIDS-related illness (delayed treatment group). Primary events
were AIDS clinical events (WHO stage 4 HIV-1 disease, tuberculosis, and severe bacterial
infections) and the following serious medical conditions unrelated to AIDS: serious cardiovascular
or vascular disease, serious liver disease, end-stage renal disease, new-onset diabetes mellitus, and
non-AIDS malignant disease. Analysis was by intention-to-treat. This trial is registered with
ClinicalTrials.gov, number NCT00074581.
Findings—1763 people with HIV-1 infection and a serodiscordant partner were enrolled in the
study; 886 were assigned early antiretroviral treatment and 877 to the delayed treatment group
(two individuals were excluded from this group after randomisation). Median CD4 counts at
randomisation were 442 (IQR 373–522) cells per μL in patients assigned to the early treatment
group and 428 (357–522) cells per μL in those allocated delayed antiretroviral treatment. In the
delayed group, antiretroviral treatment was initiated at a median CD4 count of 230 (IQR 197–249)
cells per μL. Primary clinical events were reported in 57 individuals assigned to early treatment
initiation versus 77 people allocated to delayed antiretroviral treatment (hazard ratio 0·73, 95% CI
0·52–1·03; p=0·074). New-onset AIDS events were recorded in 40 participants assigned to early
antiretroviral treatment versus 61 allocated delayed initiation (0·64, 0·43–0·96; p=0·031),
tuberculosis developed in 17 versus 34 patients, respectively (0·49, 0·28–0·89, p=0·018), and
primary non-AIDS events were rare (12 in the early group vs nine with delayed treatment). In
total, 498 primary and secondary outcomes occurred in the early treatment group (incidence 24·9
per 100 person-years, 95% CI 22·5–27·5) versus 585 in the delayed treatment group (29·2 per 100
person-years, 26·5–32·1; p=0·025). 26 people died, 11 who were allocated to early antiretroviral
treatment and 15 who were assigned to the delayed treatment group.
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Interpretation—Early initiation of antiretroviral treatment delayed the time to AIDS events and
decreased the incidence of primary and secondary outcomes. The clinical benefits recorded,
combined with the striking reduction in HIV-1 transmission risk previously reported, provides
strong support for earlier initiation of antiretroviral treatment.
Funding—US National Institute of Allergy and Infectious Diseases.
Introduction
Combination antiretroviral treatment has reduced morbidity and mortality associated with
HIV-1 infection over the past two decades.1,2 However, the best timing of treatment
initiation in people with high CD4 cell counts remains unknown. Findings of observational
studies of treatment for HIV-1 infection lend support to early initiation of antiretroviral
treatment,3–6 but data from randomised studies are scarce. In a randomised trial from Haiti,7
HIV-1 disease progression was delayed and survival extended when antiretroviral treatment
was started at CD4 counts of 200–350 cells per μL, compared with initiation at CD4 counts
of less than 200 cells per μL.
The HIV Prevention Trials Network (HPTN) 052 study is a worldwide, multicentre,
randomised controlled trial designed to compare early versus delayed antiretroviral
treatment for HIV-1-infected adults with CD4 counts of 350–550 cells per μL. Interim
results after 1·7 years of follow-up showed a 96% reduction in HIV-1 transmission to a
sexual partner and delayed time to AIDS events with early treatment.8 Here, we present a
planned analysis of HPTN 052, focusing on clinical outcomes that reflect overall recorded
morbidity and mortality related to HIV-1 infection. These outcomes might be a result of
HIV-1 disease progression, the effect of HIV-1 infection on serious non-AIDS clinical
events, adverse events resulting from treatment, or a combination of these.
Methods
Study population
We enrolled HIV-1-serodiscordant couples (one with HIV-1 infection and the other without)
from nine countries: Botswana (one site), Brazil (two sites), India (two sites), Kenya (one
site), Malawi (two sites), South Africa (two sites), Thailand (one site), the USA (one site),
and Zimbabwe (one site).8 Since the US site enrolled only two couples during the pilot
phase of the study and did not participate in the full study, the two HIV-1-infected
participants enrolled at that site were excluded from the current analyses. Inclusion criteria
were a CD4 count of 350–550 cells per μL in the HIV-1-infected member of every couple
(index case) and no previous long-term use of antiretroviral treatment. The study protocol
was approved by the institutional review board or ethics committee at every site, in addition
to other local regulatory bodies as appropriate. All study participants provided written
informed consent.
Randomisation and masking
We randomly assigned HIV-1-infected participants to either early or delayed antiretroviral
treatment. Random-isation was done centrally by use of permuted blocks, and we stratified
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randomisation by study site.8 Participants and clinicians were aware of their treatment
allocation.
Outcomes
Primary clinical outcomes were death, new-onset WHO stage 4 HIV-1 disease, tuberculosis,
severe bacterial infections, serious cardiovascular or vascular events, serious liver disease,
end-stage renal disease, new-onset diabetes mellitus, and non-AIDS defining malignant
diseases (appendix pp 26–27). Secondary clinical outcomes included WHO stage 2 and 3
HIV-1 events and other medical disorders such as malaria, chronic renal insufficiency,
hepatic transaminitis, lipodystrophy, dyslipidaemia, peripheral neuropathy, hypertension,
lactic acidosis, and thrombocytopenia (appendix p 28).
Procedures
Early treatment started at enrolment; delayed anti retroviral treatment started either after two
consec u tive CD4 counts of 250 cells per μL or less were recorded or after development of
an AIDS-related illness. Prophylaxis with isoniazid, co-trimoxazole
(trimethoprimsulfamethoxazole), or both, was available, according to local guidelines. After
enrolment, we did periodic clinical and laboratory assessment, measured drug adherence,
and provided counselling. Full details of study implementation and other study results have
been described elsewhere.8 We did all current data analyses in accordance with a
prespecified plan (appendix pp 1–25).
We captured incident cases of primary and secondary outcomes prospectively during the
study with a targeted case report form (appendix pp 34–41). All primary outcomes and
prespecified selected secondary outcomes underwent masked case review. We either
designated outcomes as confirmed or probable or rejected them, according to AIDS Clinical
Trials Group Criteria for Clinical and Other Events (appendix pp 42–145)9 and WHO case
definitions of HIV-1 for surveillance and revised clinical staging and immunological
classification of HIV-1-related disease in adults and children.10 We reviewed the study
database further for laboratory events, including persistent elevation of hepatic
aminotransferase enzymes or creatinine and thrombo cytopenia (appendix p 28). In all
analyses, we pooled outcomes across disposition (confirmed or probable). With the
exception of recurrent tuberculosis, bacterial infections, malaria, anaemia, and transaminitis
after resolution, we did not include repeat events.
Statistical analysis
We estimated time to first primary outcome with the Kaplan-Meier method and compared
the dist ri butions by treatment group with the log-rank test. We summarised distributions
with cumulative event probabilities over 2 years (median follow-up). The incidence of
primary outcomes, and combined primary and secondary outcomes, were estimated by
treatment group with Poisson regression. We used robust standard errors to accommodate
multiple and repeated events. In secondary analyses, using methods described previously,8
we examined the cumulative incidence of prespecified subcategories of primary outcomes:
AIDS events (including WHO stage 4 events, tuberculosis, and severe bacterial infections),
non-AIDS events, and deaths. We calculated the relative hazard of primary outcomes for
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delayed versus early treatment by prespecified sub groups (geographical region, sex, and
baseline CD4 count [<450 cells per μL vs ≥450 cells per μL]) using Cox proportional-
hazards regression. We used Cox regression stratified by geographical region to examine
factors associated with the hazard of primary outcome. One analysis only included
pretreatment risk factors and a covariate for treatment group; a second analysis included a
time-updated covariate for proximal CD4 cell count (the CD4 cell count measured closest to
each observed event time) and, thus, did not include a treatment group covariate.11 All
estimated effect sizes are given with 95% CIs.
For every participant randomly allocated to the delayed treatment group, the rate of change
in CD4 count from study entry to antiretroviral treatment initiation was estimated with least-
squares regression, using all available CD4 counts during that period. We presented the
distribution of these estimated rates of CD4 count change and all continuous outcomes as
medians and IQR.
We analysed data by intention-to-treat, irrespective of antiretroviral treatment status. We
included all data to May 11, 2011 (the day before public release of HPTN 052 primary
prevention study results), for HIV-1-infected participants enrolled at sites outside the USA.
This date was chosen because, after that time, providers and participants would make
decisions about their care based on the results of the trial, which would affect patients’
outcomes and induce bias. This Article includes 3 months’ additional follow-up, compared
with the previous analysis,8 and excludes two individuals enrolled at the US site. We
censored follow-up for all participants at May 11, 2011, or when the patient came off study,
or 6 months after their last visit, whichever occurred first.
This trial is registered with ClinicalTrials.gov, number NCT00074581.
Role of the funding source
The sponsors of the study had no role in study design, data collection, data analysis, data
interpretation, or writing of the report. The corresponding author had full access to all the
data in the study and had final responsibility for the decision to submit for publication.
Results
1763 HIV-1-infected individuals with a serodiscordant partner were enrolled in the trial and
underwent randomisation; 886 were assigned to the early treatment group and 877 were
allocated to delayed antiretroviral treatment (figure 1). Two patients from the USA were
excluded from the delayed treatment group after randomisation. Table 1 presents baseline
characteristics. Median age of participants was 33 years (IQR 27–39), and half the study
population were men. The median baseline CD4 count was 436 cells per μL (IQR 364–522),
and the median plasma viral load was 4·4 log10 copies per mL (IQR 3·8–4·9); 368 (21%)
participants had plasma HIV-1 RNA greater than 100 000 copies per mL. At enrolment, 199
(11%) participants in total were taking co-trimoxazole; at 12 months, this number had
declined to 32 (4%) in the early treatment group and 65 (8%) in the delayed treatment group.
Only 14 participants were receiving isoniazid at study entry; an additional 38 patients (25
allocated to early treatment and 13 assigned to the delayed treatment group) initiated
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prophylaxis with isoniazid during the course of the study. Median follow-up was 2·1 years
(IQR 1·5–2·9).
57 (6%) participants assigned to the early treatment group and 77 (9%) individuals allocated
to delayed antiretroviral treatment had at least one primary outcome event (table 2). The
cumulative probability of a primary outcome event over 2 years was 4·8% (95% CI 3·6–6·5)
in the early treatment group and 7·9% (6·2–10·1) in the delayed treatment group (figure 2A)
The estimated relative hazard (early vs delayed treatment) of primary events was 0·73 (95%
CI 0·52–1·03; p=0·074); no differences in the effect of early versus delayed treatment were
apparent by geographical region, sex, and baseline CD4 count (p>0·81; figure 3).
40 (5%) participants assigned to the early treatment group had AIDS events compared with
61 (7%) people allocated delayed antiretroviral treatment. The cumulative probability of
having an AIDS event over 2 years was 3·3% (2·4–4·9) in the early treatment group
compared with 6·0% (4·5–7·9) in the delayed treatment group (figure 2B). The estimated
relative hazard was 0·64 (95% CI 0·43–0·96; p=0·031).
17 (2%) people assigned early antiretroviral treatment reported a tuberculosis event versus
34 (4%) individuals who were allocated to the delayed treatment group. The cumulative
probability of tuberculosis events over 2 years was 1·2% (0·6–2·2) in patients assigned to the
early treatment group and 3·7% (2·5–5·3) in those allocated delayed antiretroviral treatment
(figure 2C). The estimated relative hazard was 0·49 (95% CI 0·28–0·89; p=0·018). With
respect to secondary outcomes, serious non-AIDS events were rare and were reported in 12
patients assigned to early antiretroviral treatment and in nine participants who were
allocated to the delayed treatment group (table 2).
26 people died, 11 who were assigned early antiretroviral treatment and 15 allocated delayed
treatment (table 2). The distribution of time to death did not differ between treatment groups
(p=0·43; figure 2D). All but three deaths have been described previously.8 The three
additional deaths were identified during the additional follow-up period: one individual
assigned to the early treatment group died from sepsis; and two people who were allocated
delayed antiretroviral treatment died from indeter minate causes. In total, five deaths were
associated with primary outcomes, and the remainder were attributable to causes that either
did not meet predefined primary outcome diagnosis criteria or were suicides, accidental
deaths, or of indeterminate cause.
162 primary outcome events were recorded in total, over 4007 person-years of follow-up,
which includes repeated and multiple outcomes in the same individual. 71 primary events
were noted in people assigned to the early treatment group (incidence 3·5 events per 100
person-years, 95% CI 2·7–4·7) versus 91 in individuals allocated delayed antiretroviral
treatment (4·5 events per 100 person-years, 3·6–5·7; p=0·19).
AIDS events were the most frequently reported outcomes, with 71 events noted in 61
patients assigned delayed antiretroviral treatment and 49 events in 40 people allocated early
treatment (p=0·089). Severe bacterial infections happened more frequently in patients
assigned early treatment (20 events in 20 people) than in those allocated delayed
antiretroviral treatment (15 events in 13 patients). 54 cases of tuberculosis were recorded in
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51 participants: 17 were noted in people allocated early treatment (incidence 0·8 events per
100 person-years, 95% CI 0·5–1·4) and 37 were reported in individuals allocated delayed
antiretroviral treatment (1·8 events per 100 person-years, 95% CI 1·3–2·6; p=0·009).
Tuberculosis cases are presented in the appendix (pp 29–33).
On multivariable analysis of baseline factors associated with time to first primary outcome
(figure 4A), a higher risk was noted with older age (p=0·017), higher baseline HIV-1 RNA
titre (p=0·013), an amount of haemoglobin less than 85 g/L (p=0·025), and hepatitis B virus
co-infection (p=0·040). The estimated effect of early versus delayed antiretroviral treatment
was unchanged after adjustment for these baseline factors. A proximal (time-updated)
increase in CD4 cell count of 50 cells per μL was associated with a 10% lower hazard of a
primary outcome (hazard ratio 0·90, 95% CI 0·85–0·95; p=0·001; figure 4B).
To provide a more comprehensive measure of the clinical effect of early versus delayed
antiretroviral treatment in individuals with HIV-1 infection, secondary outcomes in our
study included WHO stage 2 and 3 events and other medical disorders reflecting HIV-1
disease, potential toxic effects of drugs, or both. 615 (35%) participants had at least one such
secondary outcome (table 3), 298 (34%) in patients assigned to the early treatment group
and 317 (36%) in those allocated delayed antiretroviral treatment. The most frequently
reported secondary outcomes were recurrent upper-respiratory-tract infections, moderate and
severe unexplained weight loss, smear-positive malaria, papular pruritic eruptions, herpes
zoster, and persistent candidosis (table 3). Of note, secondary events potentially associated
with antiretroviral treatment included dyslipidaemia and lipodystrophy, and these disorders
were most frequently reported in patients allocated early antiretroviral treatment, whereas
other events linked to antiretroviral treatment—eg, peripheral neuro pathy, hepatic
transaminitis and chronic renal failure—were not (table 3).
Primary and secondary outcomes combined were reported in 326 (37%) patients assigned
early anti-retroviral treatment and in 347 (40%) participants allocated to the delayed
treatment group (table 3). The incidence of all primary and secondary outcomes was lower
in participants randomly allocated to early antiretroviral treatment (24·9 events per 100
person-years, 95% CI 22·5–27·5) than in individuals assigned to the delayed treatment group
(29·2 events per 100 person-years, 95% CI 26·5–32·1; p=0·025). This difference was driven
by HIV-1-related outcomes.
213 (24%) participants assigned to the delayed treatment group ultimately began
antiretroviral treatment. Median time to treatment initiation was 3·8 years from enrolment
(95% CI 3·5–4·4; figure 5A), with a median CD4 count of 230 cells per μL (IQR 197–249)
and median HIV-1 RNA titre of 5·0 log10 copies per mL (IQR 4·5–5·5) at treatment
initiation. Median duration of antiretroviral treatment was 2·1 years (IQR 1·5–2·9) for
patients assigned early treatment and 1·0 years (0·5–1·7) for individuals allocated to the
delayed group. Choice of antiretroviral drug has been described previously and was
predominantly a combination of zidovudine, lamivudine, and efavirenz.8 In the early
treatment group, the proportion of individuals with an HIV-1 RNA titre less than 400 copies
per mL remained greater than 89% for the entire follow-up. A gradual increase in the
proportion of people with an HIV-1 RNA titre less than 400 copies per mL was noted in the
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delayed treatment group, which grew as HIV-1-infected study participants began
antiretroviral treatment (figure 5B). Overall, the median change in CD4 count over 2 years
was a 225 cells per μL increase (IQR 96 to 373 increase) in patients allocated to early
antiretroviral treatment, compared with a median change in CD4 count in the delayed
treatment group of a 37 cells per μL decline (IQR 123 decline to 51 increase; figure 5C).
Before starting antiretroviral treatment, the median change in CD4 count was a 39 cells per
μL decline (IQR 0 to 80 decline) in patients allocated to the delayed treatment group per
year, but after treatment initiation, the CD4 count changed by a similar extent in both groups
(median change of 246 cells per μL increase [IQR 144 to 384 increase] over 2 years).
However, the CD4 count in people allocated to early antiretroviral treatment remained
higher than in those assigned to the delayed treatment group over the course of the study
(figure 5D).
Primary and secondary endpoints were not concentrated among participants with low CD4
counts; in fact, most outcome events were recorded when the most recent CD4 count was
higher than 350 cells per μL (figure 6). The median CD4 count for primary clinical events
was 353 cells per μL (IQR 301–425) in patients assigned to delayed antiretroviral treatment
compared with 502 cells per μL (417–653) in participants allocated to the early treatment
group.
Discussion
Our findings from the HPTN 052 study cohort show the broader clinical effect of early
initiation of antiretroviral treatment, including effects in relation to serious non-AIDS
medical disorders and HIV-1-associated events. Time to first serious clinical event was
longer in patients assigned early antiretroviral treatment, despite the fact that serious non-
AIDS events were uncommon. However, a substantial number of AIDS-related and HIV-1-
related events were recorded among study participants despite fairly high baseline CD4
counts. Time to an AIDS event was longer in patients allocated to the early treatment group
than in those assigned delayed antiretroviral treatment (p=0·031); similarly, the overall
incidence of primary or secondary outcomes was higher in the delayed group, predominantly
tuberculosis and WHO stage 2 and 3 events (p=0·025).
The results of our current multicentre randomised study extend previous study findings
(panel).12 We have reported8 that antiretroviral treatment prevents 96% of HIV-1
transmission events from an infected individual to their sexual partner when initiated at CD4
counts of 350–550 cells per μL, compared with starting treatment at a CD4 count lower than
250 cells per μL; further, antiretroviral treatment was associated with a reduction in AIDS
events. Findings of the Comprehensive International Program of Research on AIDS
(CIPRA) study, done in Haiti,7 showed a benefit when antiretroviral treatment was initiated
at CD4 counts between 250 and 350 cells per μL compared with counts lower than 200 cells
per μL. Post-hoc analysis of a subset of antiretroviral treatment-naive people, and patients
off-therapy who had been treated previously, who were enrolled in the Strategies for
Management of Antiretroviral Therapy (SMART) randomised controlled trial, showed a
benefit of earlier antiretroviral treatment,13 with most events occurring in previously treated
individuals. Detailed analyses of several large cohorts show a benefit of treatment initiation
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at higher CD4 cell counts.3–6 The strengths and limitations of these earlier studies have been
addressed.6,14,15
The burden of AIDS and mortality seen in our study, and in other cohorts in Africa,16 is
higher than in European populations with similar CD4 counts.17 Time-to-first AIDS event
was significantly longer in patients allocated to the early treatment group than in those
assigned to delayed antiretroviral treatment. This difference mainly reflects prevention of
tuberculosis, which is a leading cause of death in people living with HIV-1 infection.18 The
noted reduction in risk is similar to that seen in the CIPRA study7 and accords with the 65%
reduction in tuberculosis incidence associated with use of antiretroviral treat ment across all
CD4 counts that was reported in a meta-analysis.19 We recorded both pulmonary and
extrapulmonary tuberculosis in our study participants (appendix pp 29–33). The frequency
of extrapulmonary tuberculosis in people with HIV-1 infection,20,21 and difficulties in
diagnosis of extrapulmonary tuberculosis,22,23 have been noted. Prevention of tuberculosis
ascribed to antiretroviral treatment provides an important rationale for early treatment of
HIV-1 infection. Addition of isoniazid to antiretroviral treatment could potentially decrease
tuberculosis incidence further.24
In this report, we included clinical outcomes that might result not only from HIV-1 infection
but also from antiretroviral treatment, to provide a more complete picture of the health of
individuals living with HIV-1 infection. Early antiretroviral treatment reduced the incidence
of WHO stage 2 and 3 events; although such events are not life-threatening, they can lead to
substantial morbidity, even among patients with high CD4 counts.16 Not unexpectedly,
dyslipidaemia and lipodystrophy were recorded more frequently in patients assigned to the
early treatment group versus those allocated to delayed antiretroviral treatment. We reported
previously that serious (grade 3 and 4) laboratory toxic effects were uncommon in both
treatment groups.8 In this study, we focused on serious clinical diagnoses that might be a
result of adverse effects of treatment or HIV-1, including dyslipidaemia, end-stage renal
disease, and serious liver disease. Our analyses did not include a focus on anaemia,
neutropenia, and psychiatric events,8 which were numerically more common with early
antiretroviral treatment possibly because of use of zidovudine or efavirenz.25
Complications unrelated to AIDS are an emerging concern in resource-limited settings.26,27
In this current analysis, the reported incidence of non-AIDS events was low, with no
difference recorded between study groups. Serious adverse events possibly attributable to
anti-retroviral treatment were also infrequent.8 The short duration of follow-up restricts our
ability to note cardiovascular, renal, hepatic, or malignant events that might be associated
with untreated HIV-1 infection. Long-term complications of antiretroviral treatment might
also not be apparent in view of the duration of follow-up. After unmasking of the results of
HPTN 052, all HIV-1-infected study participants were offered antiretroviral treatment,8,28
most of whom have chosen to initiate treatment.28 We continue to follow up couples
enrolled in HPTN 052 for complications arising from the delay in antiretroviral treatment
initiation, and for additional HIV-1 transmission events.
Although prevention of most clinical events was favoured by early initiation of antiretroviral
treatment, we did not record an effect on all-cause mortality. This finding is possibly
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accounted for by the lower risk of death within the range of CD4 cell counts (350–550 cells
per μL) assessed in our study and the high-quality clinical care provided at the study sites,
which guaranteed that patients presenting with disease progression would receive
antiretroviral treatment.
Initiation of antiretroviral treatment had the anticipated therapeutic benefits on HIV-1 RNA
titres and CD4 cell counts. HIV-1 RNA was suppressed for most participants, and CD4 cell
counts rose after treatment was started. In patients assigned to delayed antiretroviral
treatment, CD4 counts fell without any treatment and rose once treatment was initiated, at a
similar rate to that noted in people allocated to the early treatment group. However, the
absolute CD4 cell count did not reach the level recorded in individuals assigned to early
antiretroviral treatment, suggesting that delayed treatment might diminish or defer full
restoration of immunity.29
The decision about when to start antiretroviral treatment has led to policy recommendations
that differ across organisations and countries—differences that, in part, are based on
resources.12,30–32 We believe the decision to initiate antiretroviral treatment must take into
consideration the complex mix of the public health benefits of reduced HIV-1 transmission
ascribed to antiretroviral treatment8 and the potential costs and benefits to every individual
who is infected with HIV-1. On the basis of our study results, early antiretroviral treatment
—defined as initiation of antiretroviral treatment at a CD4 count of 350–550 cells per μL—
can be expected to delay the time to AIDS-defining events, tuberculosis, and WHO stage 2
and 3 events and significantly reduce the incidence of these events, compared with patients
in whom antiretroviral treatment is delayed until CD4 counts reach less than 250 cells per
μL. The absolute differences recorded between groups in clinical events were modest.
However, they offer the potential for reduced morbidity among the millions of people with
HIV-1 infection. Coupling clinical benefit with a striking effect on transmission risk gives
additional strength to the argument for early initiation of antiretroviral treatment.
Supplementary Material
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Panel: Research in context
Systematic review
In 2013, WHO did a systematic review12 to address when to start antiretroviral treatment
for individuals living with HIV-1 infection with CD4 cell counts higher than 350 cells
per μL. The review considered results from three clinical trials and 21 observational
studies. The effects of early antiretroviral treatment on morbidity, mortality, and
immunological and virological outcomes were studied. The findings showed that
initiation of antiretroviral treatment at a CD4 count greater than 350 cells per μL,
compared with treatment at a CD4 count of 350 cells per μL or lower, reduced the risk of
progression to AIDS or death, cut the risk of tuberculosis, diminished the risk of
developing a non-AIDS-defining illness, and increased the likelihood of immune
recovery. Further analysis showed a decreased risk of death with early initiation of
antiretroviral treatment in 13 studies and a diminished risk of progression to AIDS or
death in nine studies.
Interpretation
HIV Prevention Trials Network (HPTN) 052 is the first randomised controlled trial, with
study sites from nine countries in four continents, to directly compare early versus
delayed antiretroviral treatment for HIV-1-infected adults with CD4 counts of 350–550
cells per μL. We assessed a broad range of clinical outcomes that reflect overall HIV-1-
related morbidity and mortality that might be related to disease progression, and we
looked at the effect of HIV-1 infection on serious clinical events unrelated to AIDS and
adverse events resulting from antiretroviral treatment. Our findings show that early
antiretroviral treatment delayed the time to AIDS events, tuberculosis, and WHO stage 2
and 3 events and significantly reduced the incidence of these events, compared with
patients for whom antiretroviral treatment was delayed until CD4 cell counts reached less
than 250 cells per μL. Early antiretroviral treatment led to a rapid rise in CD4 cell counts
to near normal levels. Our results, combined with the striking reduction in risk of HIV-1
transmission resulting from suppression of HIV-1 replication, provide strong support for
early initiation of antiretroviral treatment.
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Figure 2. Kaplan-Meier curves showing time to primary and secondary outcomes
(A) Primary outcome. (B) First AIDS event. (C) First tuberculosis event. (D) Death.
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Figure 3. Forest plot showing relative hazard of primary outcome for early versus delayed
treatment
Errors bars show 95% CI. *Test against the null hypothesis of no treatment modification by
given subgroup (interaction).
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Figure 4. Forest plots showing risk factors for primary outcome
Errors bars show 95% CI. (A) Treatment group and risk factors at study entry. (B) Risk
factors at study entry with time-updated CD4 count.
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Figure 5. Plots showing time to initiation of treatment, HIV-1 RNA amounts, and CD4 counts
(A) Initiation of antiretroviral treatment in patients assigned to the delayed treatment group.
Dotted lines represent median time to treatment initiation. Shaded blue region represents
95% CIs. (B) Proportion of participants with HIV-1 RNA <400 copies per mL. Error bars
represent 95% CIs. (C) Median CD4 count in the intention-to-treat population. Error bars
represent IQR. (D) Median CD4 count after initiation of antiretroviral treatment. Error bars
represent IQR. For readability, outcomes at each timepoint for the delayed group are shifted
slightly off-centre.
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Distribution of CD4 counts at study visit before outcome
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Table 1
Baseline characteristics
Early treatment (n=886) Delayed treatment (n=875)
Age
    <25 years 112 (13%) 117 (13%)
    25-39 years 563 (64%) 559 (64%)
    ≥40 years 211 (24%) 199 (23%)
Women 432 (49%) 441 (50%)
Region
    South America 142 (16%) 134 (15%)
    Africa 267 (30%) 264 (30%)
    Asia 477 (54%) 477 (55%)
HIV1 RNA (log10 copies per mL) 4·4 (3·8-4·9) 4·4 (3·9-4·9)
    Missing data 3 4
CD4 count (cells per μL) 442 (373-522) 428 (357-522)
    Missing data 6 5
Hepatitis B positive 46 (5%) 45 (5%)
Haemoglobin (≥85 g/L) 36 (4%) 46 (6%)
History of tuberculosis 21 (2%) 16 (2%)
Ongoing tuberculosis 23 (3%) 18 (2%)
    Active treatment
* 10 5
    Maintenance treatment 13 13
Isoniazid prophylaxis 5 (1%) 9 (1%)
Co-trimoxazole prophylaxis 98 (11%) 101 (12%)
Data are number of participants (%) or median (IQR).
*
HIV-1-infected participants were ineligible for the study if they were in the intensive phase of tuberculosis treatment; these 15 individuals
enrolled during the intensive phase of tuberculosis treatment constitute eligibility violations but were included in all analyses.
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Table 2
Summary of primary and secondary outcomes




Any serious clinical event 57 (6%) 77 (9%) 0.73 (0·52-1·03) 0·074
Any AIDS event 40 (5%) 61 (7%) 0-64 (0·43-0·96) 0·031
Tuberculosis 17 (2%) 34 (4%) 0·49 (0·28-0·89) 0·018
Severe bacterial infection
* 20 (2%) 13 (1%) · · · ·
Any WHO stage 4 event (excluding
tuberculosis)
9 (1%) 19 (2%) · · · ·
Chronic herpes simplex
† 2 8 · · · ·
Oesophageal candidosis 2 2 · · · ·
Recurrent severe bacterial pneumonia
* 2 1 · · · ·
Invasive cervical carcinoma 0 2 · · · ·
Wasting syndrome due to HIV-1 infection 0 2 · · · ·
Kaposi's sarcoma 1 1 · · · ·
Recurrent septicaemia 2 0 · · · ·
Extrapulmonary cryptococcosis 1 0 · · · ·
HIV-1-related encephalopathy 0 1 · · · ·
Pneumocystis pneumonia 0 1 · · · ·
Primary CNS lymphoma 0 1 · · · ·
Secondary events
Non-AIDS event 12 (1%) 9 (1%)
1·35 (0·57-3·19)
† 0·50
    Diabetes mellitus 4 5 · · · ·
    Non-AIDS malignant disease 3 3 · · · ·
    Serious cardiovascular or vascular
disease
3 1 · · · ·
    Serious liver disease 2 0 · · · ·
    End-stage renal disease 0 0 · · · ·
Mortality
All deaths 11 (1%) 15 (2%)
0·73 (0·34-1·59)
† 0·43
    Deaths associated with a primary event 1 4 · · · ·
    Deaths from other causes 10 11 · · · ·
Data are the number (%) of participants who had at least one such type of outcome. All primary events underwent masked review to ensure they
met prespecified diagnostic criteria.
*
One recurrent severe bacterial pneumonia event reported in the primary paper8 was changed to severe bacterial infection by the site clinician after
the data lock for the primary paper.
†
One chronic herpes simplex event reported previously in the primary paper8 was rejected by masked review and, thus, was excluded from this
table.
‡
Post-hoc analyses that did not form part of the original study analysis plan.
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Table 3
Summary of targeted events
Early treatment (n=886) Delayed treatment (n=875)
Any targeted event (including primary events) 326 (37%) 347 (40%)
Non-primary targeted event 298 (34%) 317 (36%)
WHO stage 2 or 3 event 210 (24%) 250 (29%)
Upper-respiratory-tract infection 72 87
Moderate unexplained weight loss 76 61
Papular puritic eruptions 33 52
Herpes zoster (shingles) 17 53
Persistent oral candidosis 22 47
Unexplained severe weight loss 37 21
Seborrhoeic dermatitis 7 18
Oral ulcerations 10 9
Fungal nail infections 5 10
Oral hairy leukoplakia 3 10
Angular cheilitis 7 6
Unexplained anaemia 0 6
Acute necrotising ulcerative stomatitis, gingivitis, or periodontitis 0 4
Unexplained chronic diarrhoea 0 1
Other targeted medical disorder
    Smear-positive malaria 49 49
    Peripheral neuropathy 15 14
    Dyslipidaemia 23 7
    Hypertension 12 8
    Lipodystrophy 10 0
    Hepatic transaminitis 9 8
    Thrombocytopenia 3 6
    Lactic acidosis (symptomatic) 1 1
    Chronic renal insufficiency 0 0
Data are the number (%) of participants who had at least one such type of outcome.
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